Sinovac Announces Re-Election of All Directors at Annual General Meeting
Asks Delaware Court of Chancery to Determine Whether Dissident Shareholders Triggered Sinovac's Shareholder Rights Plan Board Approves Extension of Shareholder Rights Plan to March 27, 2019 Company Files Lawsuit in Federal District Court against Dissident Shareholders for Violating U.S. Securiti...
Sinovac Provides Update on Going Private Transaction
BEIJING, Feb. 7, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, today announced that, in connection with its previously announced going private transaction, the Company has filed a going-private trans...
Sinovac Holds 2017 Annual General Meeting of Shareholders
BEIJING, Feb. 7, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, announced today that it held its 2017 Annual General Meeting of Shareholders onTuesday, February 6, 2018 in Beijing, PRC. The Company i...
Sinovac Schedules 2017 Annual Meeting of Shareholders
BEIJING, Dec. 29, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products inChina, announced today that it will hold its 2017 Annual Meeting of Shareholders onTuesday, February 6, 2018 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 S...
Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health Organization
BEIJING, Dec. 22, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) (the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China, announced today that it has received a positive decision from the World Health Organization ("WHO") on the acceptability, in principle,...
Sinovac Biotech Cures Nasdaq Filing Deficiency
BEIJING, Dec. 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) (the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China, announced today that it has received a Nasdaq Staff letter indicating that the Form 20-F filing delinquency, which was the subject of a ...
Sinovac Reports Unaudited First Half of 2017 Financial Results
BEIJING, Dec. 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, announced today that it reported its unaudited financial results for the six months endedJune 30, 2017. Financial Highlights * Sale...
Sinovac Biotech Announces Update on Nasdaq Matters
BEIJING, Nov. 30, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) (the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China, announced today that the Nasdaq Hearings Panel (the "Panel") granted the Company's request to extend the stay of suspension in trading ...
Sinovac Files 2016 Annual Report on Form 20-F and Reports Unaudited Fourth Quarter 2016 Financial Results
BEIJING, Nov. 22, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the"Company"), a leading provider of biopharmaceutical products in China, announced today that it has filed its 2016 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ende...
Sinovac Biotech Announces Request Hearing before Nasdaq Hearings Panel
BEIJING, Nov. 8, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) (the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China, announced today that the Company submitted a request for a hearing before the Nasdaq Hearings Panel (the "Panel"). As reported on Novem...
Sinovac Biotech Announces Receipt of Delisting Determination Letter from Nasdaq
BEIJING, Nov. 3, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) ("Sinovac"), a leading provider of biopharmaceutical products inChina, announced today that onNovember 1, 2017, the Company received a delisting determination letter from the Staff of the Listing Qualifications Department (...
Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for Varicella Vaccine Candidate Against Chickenpox
BEIJING, Sept. 25, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of vaccines inChina, announced today preliminary top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the Company's proprietary Varicella vaccine against Chickenp...
Sinovac Biotech Announces Certain Updates Relating to Delayed Filing of Annual Report on Form 20-F
BEIJING, Aug. 14, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA)(" Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that The NASDAQ Stock Market ("NASDAQ") has accepted the Company's plan to regain compliance with NASDAQ Listing Rule 5...
UPDATE: To Acquire Sinovac Biotech (Nasnaq: SVA) Sinobioway Consortium Raises Its Purchase Price To $8 Per Share
NEW YORK, June 30, 2017 /PRNewswire/ --To Acquire Sinovac Biotech (Nasnaq: SVA) Sinobioway Consortium Raises Its Purchase Price To$8 Per Share. On the evening of June 26, 2017 Beijing time, Sinovac Biotech Ltd. (Nasdaq: SVA, "Sinovac") announced that Sinovac entered into a Definitive Agreement ...
To Fight Against The Behavior Between Sinovac's Special Committee And Weidong Yin's Consortium And Their Low Price, Sinobioway Consortium Raises Its Purchase Price To $8 Per Share
NEW YORK, June 28, 2017 /PRNewswire/ -- On the evening of June 26, 2017 Beijing time,Sinovac Biotech Ltd. (Nasdaq: SVA, "Sinovac") announced that Sinovac entered into a Definitive Agreement ("Amalgamation Agreement") for Going-Private Transaction withWeidong Yin's consortium ("Consortium A") whic...
Sinovac Biotech Ltd. Enters into Definitive Agreement for Going-Private Transaction
BEIJING, June 26, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, today announced that it has entered into a definitive amalgamation agreement (the "Amalgamation Agreement") with Sinovac (Cayman) Lim...
Sinovac Biotech Announces Receipt of NASDAQ Letter and Delayed Filing of Annual Report on Form 20-F
BEIJING, May 16, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA)("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, announced today that it is delaying its Annual Report on Form 20-F for the year endedDecember 31, 2016 (the "2016 Annual Report") and t...
Sinovac Reports Announces Filing Extension for 2016 Annual Report
BEIJING, May 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products inChina, has filed a Form 12b-25 Notification of Late Filing with the U.S. Securities and Exchange Commission that discloses that the Company is unable to file its annual repo...
